Spinocerebellar ataxia

Spinocerebellar ataxia (SCA) is a progressive, degenerative,[1] genetic disease with multiple types, each of which could be considered a neurological condition in its own right. An estimated 150,000 people in the United States have a diagnosis of spinocerebellar ataxia at any given time. SCA is hereditary, progressive, degenerative, and often fatal. There is no known effective treatment or cure. SCA can affect anyone of any age. The disease is caused by either a recessive or dominant gene. In many cases people are not aware that they carry a relevant gene until they have children who begin to show signs of having the disorder.[2]

This article is about a malady of the brain. For other uses, see SCA (disambiguation).
Spinocerebellar ataxia
Other namesSpinocerebellar atrophy or Spinocerebellar degeneration
Cerebellum (in blue) of the human brain
SpecialtyNeurology 

Signs and symptoms

Spinocerebellar ataxia (SCA) is one of a group of genetic disorders characterized by slowly progressive incoordination of gait and is often associated with poor coordination of hands, speech, and eye movements. A review of different clinical features among SCA subtypes was recently published describing the frequency of non-cerebellar features, like parkinsonism, chorea, pyramidalism, cognitive impairment, peripheral neuropathy, seizures, among others.[3] As with other forms of ataxia, SCA frequently results in atrophy of the cerebellum,[4] loss of fine coordination of muscle movements leading to unsteady and clumsy motion, and other symptoms.

The symptoms of an ataxia vary with the specific type and with the individual patient. In many cases a person with ataxia retains full mental capacity but progressively loses physical control.

Cause

The hereditary ataxias are categorized by mode of inheritance and causative gene or chromosomal locus. The hereditary ataxias can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner.

  • Many types of autosomal dominant cerebellar ataxias for which specific genetic information is available are now known. Synonyms for autosomal-dominant cerebellar ataxias (ADCA) used prior to the current understanding of the molecular genetics were Marie's ataxia, inherited olivopontocerebellar atrophy, cerebello-olivary atrophy, or the more generic term "spinocerebellar degeneration." (Spinocerebellar degeneration is a rare inherited neurological disorder of the central nervous system characterized by the slow degeneration of certain areas of the brain. There are three forms of spinocerebellar degeneration: Types 1, 2, 3. Symptoms begin during adulthood.)
  • There are five typical autosomal-recessive disorders in which ataxia is a prominent feature: Friedreich ataxia, ataxia-telangiectasia, ataxia with vitamin E deficiency, ataxia with oculomotor apraxia (AOA), spastic ataxia. Disorder subdivisions: Friedreich's ataxia, Spinocerebellar ataxia, Ataxia telangiectasia, Vasomotor ataxia, Vestibulocerebellar, Ataxiadynamia, Ataxiophemia, Olivopontocerebellar atrophy, and Charcot-Marie-Tooth disease.
  • There have been reported cases where a polyglutamine expansion may lengthen when passed down, which often can result in an earlier age-of-onset and a more severe disease phenotype for individuals who inherit the disease allele. This falls under the category of genetic anticipation.[5] Several types of SCA are characterized by repeat expansion of the trinucleotide sequence CAG in DNA that encodes a polyglutamine repeat tract in protein. The expansion of CAG repeats over successive generations appears to be due to slipped strand mispairing during DNA replication or DNA repair.[6]

Diagnosis

Classification

A few SCAs remain unspecified and can not be precisely diagnosed, but in the last decade genetic testing has allowed precise identification of dozens of different SCAs and more tests are being added each year.[7] In 2008, a genetic ataxia blood test developed to test for 12 types of SCA, Friedreich's ataxia, and several others. However, since not every SCA has been genetically identified some SCAs are still diagnosed by neurological examination, which may include a physical exam, family history, MRI scanning of the brain and spine, and spinal tap.[8]

Many SCAs below fall under the category of polyglutamine diseases, which are caused when a disease-associated protein (i.e., ataxin-1, ataxin-3, etc.) contains a large number of repeats of glutamine residues, termed a polyQ sequence or a "CAG trinucleotide repeat" disease for either the one-letter designation or codon for glutamine respectively. The threshold for symptoms in most forms of SCA is around 35, though for SCA3 it extends beyond 50. Most polyglutamine diseases are dominant due to the interactions of resulting polyQ tail.

The first ataxia gene was identified in 1993 and called "Spinocerebellar ataxia type 1" (SCA1); later genes were called SCA2, SCA3, etc. Usually, the "type" number of "SCA" refers to the order in which the gene was found. At this time, there are at least 29 different gene mutations that have been found.

The following is a list of some of the many types of Spinocerebellar ataxia.

SCA Type Average Onset
(Range in Years)		 Average Duration
(Range in Years)		 What the patient experiences Common origin Problems
with DNA
SCA1[9] (ATXN1) 4th decade
(<10 to >60)		 15 years
(10–35)		 Hypermetric saccades, slow saccades, upper motor neuron
(note: saccades relates to eye movement)		   CAG repeat, 6p (Ataxin 1)
SCA2[10] (ATXN2) 3rd–4th decade
(<10 to >60)		 10 years
(1–30)		 Diminished velocity saccades
areflexia (absence of neurologic reflexes)		 Cuba CAG repeat, 12q
SCA3[11] (MJD) (ATXN3) 4th decade
(10–70)		 10 years
(1–20)		 Also called Machado-Joseph disease (MJD)[12]
Gaze-evoked nystagmus (a rapid, involuntary, oscillatory motion of the eyeball)
upper motor neuron
slow saccades		 Azores
(Portugal)		 CAG repeat, 14q
SCA4 (PLEKHG4) 4th–7th decade
(19–72)		 Decades areflexia (absence of neurologic reflexes)   Chromosome 16q
SCA5 (SPTBN2) 3rd–4th decade
(10–68)		 >25 years Pure cerebellar   Chromosome 11
SCA6[13] (CACNA1A) 5th–6th decade
(19–71)		 >25 years Downbeating nystagmus, positional vertigo
Symptoms can appear for the first time as late as 65 years old.		   CAG repeat, 19p
Calcium channel gene
SCA7[14] (ATXN7) 3rd–4th decade
(0.5–60)		 20 years
(1–45; early onset correlates with shorter duration)		 Macular degeneration, upper motor neuron, slow saccades   CAG repeat, 3p (Ataxin 7)
SCA8[15] (IOSCA) 39 yrs
(18–65)		 Normal lifespan Horizontal nystagmus (a rapid, involuntary, oscillatory motion of the eyeball), instability, lack of coordination   CTG repeat,[16] 13q
SCA10[17] (ATXN10) 36 years 9 years ataxia, seizures Mexico Chromosome 22q linked
pentanucleotide repeat
SCA11 (TTBK2) 30 yrs
(15–70)		 Normal lifespan Mild, remain ambulatory (able to walk about on one's own)   15q
SCA12[18] (PPP2R2B) 33 yrs
(8–55)		   Head and hand tremor,
akinesia (loss of normal motor function, resulting in impaired muscle movement)		   CAG repeat, 5q
SCA13 (KCNC3) Childhood or adulthood depending on mutation Depending on KCNC3 (a kind of gene) Mental retardation   19q
SCA14[19] (PRKCG) 28 yrs
(12–42)		 Decades
(1–30)		 Myoclonus (a sudden twitching of muscles or parts of muscles, without any rhythm or pattern, occurring in various brain disorders)   19q
SCA16 (ITPR1) 39 yrs
(20–66)		 1–40 years Head and hand tremor   8q
SCA17 (TBP)   CAG repeat, 6q (TATA-binding protein)
SCA19, SCA22 (KCND3[20])     Mild cerebellar syndrome, dysarthria    
SCA25 1.5–39 yrs Unknown ataxia with sensory neuropathy, vomiting and gastrointestinal pain.   2p
SCA27[21] (FGF14[20]) 15–20 yrs Unknown ataxia with poor cognition, dyskinesias and tremor.   FGF14 13q34
SCA35 40–48 years Unknown gait and limb ataxia, dysarthria, ocular dysmetria, intention tremor, pseudobulbar palsy, spasmodic torticollis, extensor plantar responses, reduced proprioception and hyperreflexia China transglutaminase 6 (TGM6) located at chromosome 20p13

Others include SCA18, SCA20, SCA21, SCA23, SCA26, SCA28, and SCA29.

Four X-linked types have been described ( 302500, 302600, 301790, 301840), but only the first of these has so far been tied to a gene (SCAX1).

Name OMIM RareDiseases Other
Anemia, sideroblastic spinocerebellar ataxia; Pagon Bird Detter syndrome 301310 Disease ID 668 at NIH's Office of Rare Diseases
Friedreich's ataxia; Spinocerebellar ataxia, Friedreich 229300 Disease ID 6468 at NIH's Office of Rare Diseases
Infantile onset Spinocerebellar ataxia 605361 Disease ID 4062 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 1 164400 Disease ID 4071 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 2 183090 Disease ID 4072 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 3; Machado Joseph disease 109150 Disease ID 6801 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 4 600223 Disease ID 9970 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 5 600224 Disease ID 4953 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 7 164500 Disease ID 4955 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 8 603680 Disease ID 4956 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 13 605259 Disease ID 9611 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 18 607458 Disease ID 9976 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 19 607346 Disease ID 9969 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 20 608687 Disease ID 9997 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 21 607454 Disease ID 9999 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 23 610245 Disease ID 9950 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 25 608703 Disease ID 9996 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 26 609306 Disease ID 9995 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 28 610246 Disease ID 9951 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 30 117360 Disease ID 9975 at NIH's Office of Rare Diseases
Spinocerebellar ataxia 35 613908 Disease ID at NIH's Office of Rare Diseases
Spinocerebellar ataxia amyotrophy deafness syndrome Disease ID 2451 at NIH's Office of Rare Diseases ORPHA:2074 at Orphanet
Spinocerebellar ataxia, autosomal recessive 1 606002 Disease ID 4949 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, autosomal recessive 3 271250 Disease ID 9971 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, autosomal recessive 4 607317 Disease ID 4952 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, autosomal recessive 5 606937 Disease ID 9977 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, autosomal recessive 6 608029 Disease ID 4954 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, autosomal recessive 21 - mutation in SCYL1 Online Mendelian Inheritance in Man (OMIM): 616719 ORPHA:466794
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 607250 Disease ID 10000 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, X-linked, 2 302600 Disease ID 9978 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, X-linked, 3 301790 Disease ID 9981 at NIH's Office of Rare Diseases
Spinocerebellar ataxia, X-linked, 4 301840 Disease ID 9980 at NIH's Office of Rare Diseases

Treatment

Medication

There is no cure for spinocerebellar ataxia, which is currently considered to be a progressive and irreversible disease, although not all types cause equally severe disability.[22]

In general, treatments are directed towards alleviating symptoms, not the disease itself. Many patients with hereditary or idiopathic forms of ataxia have other symptoms in addition to ataxia. Medications or other therapies might be appropriate for some of these symptoms, which could include tremor, stiffness, depression, spasticity, and sleep disorders, among others. Both onset of initial symptoms and duration of disease are variable. If the disease is caused by a polyglutamine trinucleotide repeat CAG expansion, a longer expansion may lead to an earlier onset and a more radical progression of clinical symptoms. Typically, a person afflicted with this disease will eventually be unable to perform daily tasks (ADLs).[23] However, rehabilitation therapists can help patients to maximize their ability of self-care and delay deterioration to certain extent.[24] Researchers are exploring multiple avenues for a cure including RNAi and the use of Stem Cells and several other avenues.[25]

On January 18, 2017 BioBlast Pharma announced completion of Phase 2a clinical trials of their medication, Trehalose, in the treatment of SCA3. BioBlast has received FDA Fast Track status and Orphan Drug status for their treatment. The information provided by BioBlast in their research indicates that they hope this treatment may prove efficacious in other SCA treatments that have similar pathology related to PolyA and PolyQ diseases.[26][27]

In addition, Dr. Beverly Davidson has been working on a methodology using RNAi technology to find a potential cure for over 2 decades.[28] Her research began in the mid-1990s and progressed to work with mouse models about a decade later and most recently has moved to a study with non-human primates. The results from her most recent research "are supportive of clinical application of this gene therapy".[29]

Finally, another gene transfer technology discovered in 2011 has also been shown by Dr. Davidson to hold great promise and offers yet another avenue to a potential future cure.[30]

N-Acetyl-Leucine

N-Acetyl-Leucine is an orally administered, modified amino acid that is being developed as a novel treatment for multiple rare and common neurological disorders by IntraBio Inc (Oxford, United Kingdom).[31]

N-Acetyl-Leucine has been granted multiple orphan drug designations from the U.S. Food & Drug Administration (FDA)[32] and the European Medicines Agency (EMA)[33] for the treatment of various genetic diseases, including Spinocerebellar Ataxias. N-Acetyl-Leucine has also been granted Orphan Drug Designations in the US and EU for the related inherited cerebellar ataxia Ataxia-Telangiectasia U.S. Food & Drug Administration (FDA)[34] and the European Medicines Agency (EMA).[35]

Published case series studies have demonstrated the effects of acute treatment with N-Acetyl-Leucine for the treatment of inherited cerebellar ataxias, including Spinocerebellar Ataxias.[36][37] These studies further demonstrated that the treatment is well tolerated, with a good safety profile. A multinational clinical trial investigating N-Acetyl-L-Leucine for the treatment of a related inherited cerebellar ataxia, Ataxia-Telangiectasia, began in 2019.[38]

IntraBio is also conducting parallel clinical trials with N-Acetyl-L-Leucine for the treatment of Niemann-Pick disease type C[39] and GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).[40] Future opportunities to develop N-Acetyl-Leucine include Lewy Body Dementia,[41]Amyotrophic lateral sclerosis, Restless Leg Syndrome, Multiple Sclerosis, and Migraine[42]

Rehabilitation

Physical therapists can assist patients in maintaining their level of independence through therapeutic exercise programmes. One recent research report demonstrated a gain of 2 SARA points (Scale for the Assessment and Rating of Ataxia) from physical therapy.[43] In general, physical therapy emphasises postural balance and gait training for ataxia patients.[44] General conditioning such as range-of-motion exercises and muscle strengthening would also be included in therapeutic exercise programmes. Research showed that spinocerebellar ataxia 2 (SCA2) patients [45] with a mild stage of the disease gained significant improvement in static balance and neurological indices after six months of a physical therapy exercise training program.[46] Occupational therapists may assist patients with incoordination or ataxia issues through the use of adaptive devices. Such devices may include a cane, crutches, walker, or wheelchair for those with impaired gait. Other devices are available to assist with writing, feeding, and self care if hand and arm coordination are impaired. A randomised clinical trial revealed that an intensive rehabilitation program with physical and occupational therapies for patients with degenerative cerebellar diseases can significantly improve functional gains in ataxia, gait, and activities of daily living. Some level of improvement was shown to be maintained 24 weeks post-treatment.[47] Speech language pathologists may use both behavioral intervention strategies as well as augmentative and alternative communication devices to help patients with impaired speech.

References
  1. "spinocerebellar ataxia" at Dorland's Medical Dictionary
  2. http://www.ninds.nih.gov/disorders/ataxia/ataxia.htm%5B%5D
  3. Rossi, M; Perez-Lloret, S; Doldan, L; Cerquetti, D; Balej, J; Millar Vernetti, P; Hawkes, H; Cammarota, A; Merello, M (2014). "Autosomal dominant cerebellar ataxias: A systematic review of clinical features". European Journal of Neurology. 21 (4): 607–15. doi:10.1111/ene.12350. PMID 24765663.
  4. "Spinocerebellar ataxia". Genes and Disease [Internet]. Bethesda MD: National Center for Biotechnology Information. 1998. NBK22234. — Gives a concise description of SCA, along with a picture of shrunken degenerated cerebellum.
  5. Khristich AN, Mirkin SM (March 2020). "On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability". J. Biol. Chem. 295 (13): 4134–4170. doi:10.1074/jbc.REV119.007678. PMC 7105313. PMID 32060097.
  6. Usdin K, House NC, Freudenreich CH (2015). "Repeat instability during DNA repair: Insights from model systems". Crit. Rev. Biochem. Mol. Biol. 50 (2): 142–67. doi:10.3109/10409238.2014.999192. PMC 4454471. PMID 25608779.
  7. "Archived copy" (PDF). Archived from the original (PDF) on 2015-07-27. Retrieved 2017-01-25.CS1 maint: archived copy as title (link)
  8. www.ataxia.org
  9. sca1 at NIH/UW GeneTests
  10. sca2 at NIH/UW GeneTests
  11. sca3 at NIH/UW GeneTests
  12. machado_joseph at NINDS
  13. sca6 at NIH/UW GeneTests
  14. sca7 at NIH/UW GeneTests
  15. sca8 at NIH/UW GeneTests
  16. Mosemiller, A.K.; Dalton, J.C.; Day, J.W.; Ranum, L.P.W. (2003). "Molecular genetics of spinocerebellar ataxia type 8 (SCA8)". Cytogenetic and Genome Research. 100 (1–4): 175–83. doi:10.1159/000072852. PMID 14526178. S2CID 2292926.
  17. sca10 at NIH/UW GeneTests
  18. sca12 at NIH/UW GeneTests
  19. sca14 at NIH/UW GeneTests
  20. Perlman, Susan L. (2016). Evaluation and Management of Ataxic Disorders: An Overview for Physicians. Minneapolis: National Ataxia Foundation. p. 6. ISBN 978-0-943218-14-4. LCCN 2007923539.
  21. Online Mendelian Inheritance in Man (OMIM): 609307
  22. Jiang, Bingcheng; Glover, J.N. Mark; Weinfeld, Michael (2016). "Neurological disorders associated with DNA strand-break processing enzymes". Mechanisms of Ageing and Development. 161 (Pt A): 130–140. doi:10.1016/j.mad.2016.07.009. ISSN 0047-6374. PMC 5266678. PMID 27470939.
  23. Cruts, Marc; Engelborghs, Sebastiaan; van der Zee, Julie; Van Broeckhoven, Christine (1993). "C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia". In Adam, Margaret P.; Ardinger, Holly H.; Pagon, Roberta A.; Wallace, Stephanie E.; Bean, Lora J.H.; Stephens, Karen; Amemiya, Anne (eds.). GeneReviews. Seattle (WA): University of Washington, Seattle. PMID 25577942.
  24. Synofzik, Matthis; Ilg, Winfried (2014). "Motor Training in Degenerative Spinocerebellar Disease: Ataxia-Specific Improvements by Intensive Physiotherapy and Exergames". BioMed Research International. 2014: 583507. doi:10.1155/2014/583507. PMC 4022207. PMID 24877117.
  25. "Archived copy". Archived from the original on 2016-11-19. Retrieved 2017-01-26.CS1 maint: archived copy as title (link)
  26. "Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)". Investors Hub. Retrieved 14 October 2017.
  27. "The Orphan Genetic Disease Company: Bioblast Pharma Ltd. June 2016" (PDF). Bioblast Pharma Ltd. Retrieved 14 October 2017.
  28. Veritas, Gene (17 August 2013). "RNA Interference for Treating Huntington's Disease: An Interview with Dr. Beverly Davidson". Vimeo. Retrieved 14 October 2017.
  29. Keiser, M. S.; Kordower, J. H.; Gonzalez-Alegre, P; Davidson, B. L. (2015). "Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy". Brain. 138 (12): 3555–3566. doi:10.1093/brain/awv292. PMC 4840549. PMID 26490326.
  30. http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(1%5B%5D
  31. "IntraBio". Retrieved 2019-08-01.
  32. "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Retrieved 2019-08-01.
  33. FRANCISCO, Estela Miranda (2018-12-20). "EU/3/18/2059". European Medicines Agency. Retrieved 2019-08-01.
  34. "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Retrieved 2019-08-01.
  35. "Search Orphan Drug Designations and Approvals". www.accessdata.fda.gov. Retrieved 2019-08-01.
  36. Cross, Jo (April 2006). "MEDLINE, PubMed, PubMed Central, and the NLM". Editors' Bulletin. 2 (1): 1–5. doi:10.1080/17521740701702115. ISSN 1752-1742.
  37. Schniepp, Roman; Strupp, Michael; Wuehr, Max; Jahn, Klaus; Dieterich, Marianne; Brandt, Thomas; Feil, Katharina (2016). "Acetyl-DL-leucine improves gait variability in patients with cerebellar ataxia-a case series". Cerebellum & Ataxias. 3: 8. doi:10.1186/s40673-016-0046-2. ISSN 2053-8871. PMC 4828858. PMID 27073690.
  38. "N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-01.
  39. "N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-01.
  40. "N-Acetyl-L-Leucine for GM2 Gangliosdisosis (Tay-Sachs and Sandhoff Disease) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-01.
  41. "IntraBio". Retrieved 2019-08-01.
  42. Strupp, Michael; Bayer, Otmar; Feil, Katharina; Straube, Andreas (2019-02-01). "Prophylactic treatment of migraine with and without aura with acetyl-dl-leucine: a case series". Journal of Neurology. 266 (2): 525–529. doi:10.1007/s00415-018-9155-6. ISSN 1432-1459. PMID 30547273. S2CID 56148131.
  43. Synofzik, Matthis; Ilg, Winfried (3 April 2018). "Motor Training in Degenerative Spinocerebellar Disease: Ataxia-Specific Improvements by Intensive Physiotherapy and Exergames". BioMed Research International. 2014: 583507. doi:10.1155/2014/583507. PMC 4022207. PMID 24877117.
  44. Marsden, J.; Harris, C. (2011). "Cerebellar ataxia: Pathophysiology and rehabilitation". Clinical Rehabilitation. 25 (3): 195–216. doi:10.1177/0269215510382495. PMID 21321055. S2CID 40374830.
  45. "SCA2 information sheet from www.ataxia.org" (PDF). Archived from the original (PDF) on 2012-07-12. Retrieved 2012-05-10.
  46. Trujillo-Martín, M.Mar; Serrano-Aguilar, Pedro; Monton-Álvarez, Fernando; Carrillo-Fumero, Romen (2009). "Effectiveness and safety of treatments for degenerative ataxias: A systematic review". Movement Disorders. 24 (8): 1111–24. doi:10.1002/mds.22564. PMID 19412936.
  47. Miyai, I.; Ito, M.; Hattori, N.; Mihara, M.; Hatakenaka, M.; Yagura, H.; Sobue, G.; Nishizawa, M.; Cerebellar Ataxia Rehabilitation Trialists Collaboration (2011). "Cerebellar Ataxia Rehabilitation Trial in Degenerative Cerebellar Diseases". Neurorehabilitation and Neural Repair. 26 (5): 515–22. doi:10.1177/1545968311425918. PMID 22140200. S2CID 23764699.

Further reading
Classification
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.